INBX vs JBIO: fair value comparison
Inhibrx Biosciences, Inc. and Jade Biosciences, Inc. · Updated 2026-10-19
INBX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. JBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, INBX currently ranks higher by quality score.
| INBX | JBIO | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $89.83 | $13.47 |
| 12-month range | $28.36–$141.84 | $8.95–$26.85 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #244 of 301 Healthcare | #245 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: INBX fair value analysis · JBIO fair value analysis